BioMarin Pharmaceutical Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	1,250	942.84	755.13	724.53	587.28	649.16
Short-Term Investments	227.73	194.86	318.68	567.01	426.6	416.23
Cash & Short-Term Investments	1,478	1,138	1,074	1,292	1,014	1,065
Cash Growth	58.83%	5.95%	-16.86%	27.39%	-4.83%	41.33%
Accounts Receivable	790.27	660.54	633.7	461.32	373.4	448.35
Receivables	790.27	660.54	633.7	461.32	373.4	448.35
Inventory	1,382	1,233	1,107	894.08	776.67	698.55
Other Current Assets	204.27	201.53	141.39	104.52	110.44	129.93
Total Current Assets	3,855	3,232	2,956	2,751	2,274	2,342
Property, Plant & Equipment	1,038	1,077	1,112	1,114	1,082	1,090
Long-Term Investments	512.94	527.84	622.44	370.34	524.29	295.97
Goodwill	196.2	196.2	196.2	196.2	196.2	196.2
Other Intangible Assets	233.11	327.38	325.3	338.57	388.65	417.27
Long-Term Deferred Tax Assets	1,509	1,489	1,546	1,505	1,450	1,432
Other Long-Term Assets	270.78	138.94	83.56	98.78	89.2	74.63
Total Assets	7,615	6,989	6,842	6,375	6,005	5,848
Accounts Payable	389.67	235.4	315.51	231.24	199.68	191.43
Accrued Expenses	324.75	331.27	311.55	293.53	267.65	257.27
Current Portion of Long-Term Debt	-	-	493.88	-	-	-
Current Portion of Leases	7.58	7.57	8.78	10.38	10.46	11.75
Current Income Taxes Payable	22.61	12.57	2.65	16.21	1.21	9.66
Current Unearned Revenue	-	1.37	4.62	0.71	6.96	0.15
Other Current Liabilities	53.84	18.8	40.04	36.81	60.54	22.29
Total Current Liabilities	798.44	606.99	1,177	588.88	546.5	492.55
Long-Term Debt	596.66	595.14	593.1	1,083	1,079	1,075
Long-Term Leases	-	31.26	38.12	26.51	33.84	44.49
Other Long-Term Liabilities	163.06	97.57	81.81	73.5	79.69	129.84
Total Liabilities	1,558	1,331	1,890	1,772	1,739	1,742
Common Stock	0.19	0.19	0.19	0.19	0.18	0.18
Additional Paid-In Capital	5,901	5,802	5,612	5,405	5,192	4,993
Retained Earnings	200.78	-194.7	-621.55	-789.2	-930.76	-861.61
Comprehensive Income & Other	-45.23	50.43	-38.65	-12.73	4.74	-25.98
Shareholders' Equity	6,057	5,658	4,952	4,603	4,266	4,106
Total Liabilities & Equity	7,615	6,989	6,842	6,375	6,005	5,848
Total Debt	604.24	633.97	1,134	1,120	1,123	1,131
Net Cash (Debt)	873.6	503.74	-60.07	171.63	-109.51	-66
Net Cash Growth	166.54%	-	-	-	-	-
Net Cash Per Share	4.44	2.56	-0.31	0.91	-0.60	-0.34
Filing Date Shares Outstanding	192.11	190.78	188.68	186.53	184.03	181.83
Total Common Shares Outstanding	192.1	190.76	188.6	186.25	183.91	181.74
Working Capital	3,056	2,625	1,779	2,163	1,728	1,850
Book Value Per Share	31.53	29.66	26.25	24.71	23.19	22.59
Tangible Book Value	5,627	5,134	4,430	4,068	3,681	3,493
Tangible Book Value Per Share	29.29	26.92	23.49	21.84	20.01	19.22
Land	-	90.78	90.78	90.79	90.42	90.42
Buildings	-	892.48	860.81	819.1	774.92	761.56
Machinery	-	789.5	796.61	736.25	688.54	644.4
Construction In Progress	-	90.27	100.01	143.38	136.74	109.14
Leasehold Improvements	-	44.37	58.23	59.53	55.28	55.13

Source: S&P Global Market Intelligence. Standard template. Financial Sources.